FRAXA's Impact to Date

$
0
33.5
Million

Direct Investment in Fragile X Research

0
42

TEAMS ACTIVELY RESEARCHING FRAGILE X

Current Research Grants
0
31

PHARMACEUTICAL AND BIOMEDICAL PARTNERS

0
628

RESEARCH GRANTS AWARDED

0
19

COUNTRIES ARE HOME TO RESEARCH TEAMS

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 8,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Latest Fragile X News & Updates

View all News & Updates

A Look Back at 2022 and Ahead to 2023 Research Prospects

This holiday season you proved that the adage “actions speak louder than words” is entirely accurate. We sincerely appreciate your gifts in action. FRAXA supporters came out in full force to meet the generous $100,000 challenge offered on Giving Tuesday. By the end of the day, FRAXA had raised $269,744 thanks to matching donations! Amazing! Giving Tuesday was just the start. December ushered in a new $100,000 matching challenge from the Ralph and Ardis James Foundation – which we met! This is the second consecutive year that the Foundation has provided matching funds to accelerate Fragile X research. We are deeply grateful for the continued backing from the Ralph and Ardis James Foundation and for each donation received to advance our work. The Impact of COVID-19 on Fragile X Research We are very happy to report that we are on the rebound from COVID-19. When university labs closed around the
Read more

10 Year Vision for Fragile X Research – Dr. Elizabeth Berry-Kravis & Dr. Patricia Cogram

In this video we hear from FRAXA Investigators Dr. Patricia Cogram, Professor at the University of Chile, and Dr. Elizabeth Berry-Kravis, Professor at Rush University Medical Center as they reflect on the progress that has been made and visualize what they see happening in the next 10 years for people living with Fragile X syndrome.
Read more

Astrocyte Contribution to Sensory Hypersensitivity in Fragile X Syndrome

Most Fragile X research has focused on one type of brain cells: neurons. But mounting evidence point to problems with astrocytes, star-shaped cells which are vitally important to normal brain function. This team is working to understand how astrocytes are involved in Fragile X and develop treatment approaches that targets astrocytes alone.
Read more

Developmental Motor Phenotype in Fragile X Syndrome

One of the lesser known signs of Fragile X is unsteady walking. This is also very easy to evaluate in the clinic: no blood tests are required! With a $100,000 grant from FRAXA Research Foundation, this team will develop objective new outcome measures of gait for future treatment trials and also to see if exercise could improve other symptoms of Fragile X.
Read more

$100,000 Donor Matching Challenge From The Robert & Ardis James Foundation

We are thrilled to announce FRAXA Research Foundation’s most significant and unique matching challenge of the year, thanks to the Robert & Ardis James Foundation. This challenge will help us bring top new talent to Fragile X research.
Read more

$269,774 Raised for Fragile X Research on #GivingTuesday

Thank you very much for being a part of yet another fantastic and historic #GivingTuesday! FRAXA raised a total of $269,774 with our matching contributions!! This is incredible. Our work would be impossible without you.
Read more